先進的なBRAFV600変異性メラノーマにおけるパーソナライズド治療:REMINISCENCEプロジェクトの3件の症例報告に基づくレビュー

Christoffer Gebhardt¹, Dirk Debus², Peter Rohrer³

¹Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.

Melanoma management

|August 29, 2025

まとめ

BRAFV600変異のメラノーマ治療の最適化には,標的療法 (TT) と免疫チェックポイント阻害剤 (ICI) の配列化が含まれます. パーソナライズされた戦略は特に脳転移の患者にとって極めて重要で将来の臨床試験の指針となります

科学分野:

腫瘍学
医学遺伝学

背景:

先進的なBRAFV600変異性メラノーマの治療は複雑で,特に標的療法 (TT) と免疫チェックポイント阻害剤 (ICI) の配列化が重要です.
転移性メラノーマの患者の治療結果を最適化するには個別化された治療方法が不可欠です

研究の目的:

エンコラフェニブとビニメチニブ (EB) で治療されたBRAFV600変異のメラノーマ患者の症例報告を分析する.
パーソナライズされた治療戦略を強調し,特に脳転移のメラノーマにおけるTTとICIのシーケンスを重視する.

主な方法:

ドイツとオーストリアで治療された脳転移のメラノーマ患者の3つの症例報告の遡及分析.
既存の臨床試験データ (DREAMseq,SECOMBIT,EBIN,ImmunoCobiVem) とその限界のレビュー

主要な成果:

TTからICIへの移行の最適なタイミングは,依然として重要な臨床的課題です.
以前の治療は腫瘍の微小環境に影響を与え,臨床試験の結果の解釈を複雑にする.
循環腫瘍DNA (ctDNA) によるアプローチのような新興方法は,個別化された治療シーケンスの可能性を秘めています.

結論:

BRAFV600変異性メラノーマの有効な治療シーケンスを確立するために,将来的なバイオマーカー主導の臨床試験が緊急に必要とされています.
個々の患者プロフィールを考慮したパーソナライズされた治療戦略は,治療結果の改善に不可欠です.

キーワード:

BRAF変異のメラノーマ腫瘍学臨床的実践リアルなデータメラノーマ治療におけるシーケンシング標的型療法

さらに関連する動画

07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.5K

07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.5K

関連する概念動画

02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

関連する実験動画